The estimated Net Worth of Joseph M Lobacki is at least $178 millier dollars as of 28 September 2018. Mr. Lobacki owns over 3,000 units of Sutro Biopharma Inc stock worth over $49,327 and over the last 7 years he sold STRO stock worth over $0. In addition, he makes $128,321 as Independent Director at Sutro Biopharma Inc.
Joseph has made over 2 trades of the Sutro Biopharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of STRO stock worth $21,900 on 28 September 2018.
The largest trade he's ever made was buying 7,700 units of Sutro Biopharma Inc stock on 8 June 2018 worth over $44,583. On average, Joseph trades about 973 units every 10 days since 2018. As of 28 September 2018 he still owns at least 10,700 units of Sutro Biopharma Inc stock.
You can see the complete history of Mr. Lobacki stock trades at the bottom of the page.
Joseph M. Lobacki is an Independent Director of the Company. Mr. Lobacki is currently CEO of Artax a private biopharmaceutical company developing treatments for autoimmune and inflammatory diseases focused on modulating the T-Cell Receptor response to antigen stimulation. Previously, Mr. Lobacki served as Executive Vice President and Chief Commercial Officer for Verastem, Inc., a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of hematologic malignancies. From November 2016 to December 2017, Mr. Lobacki served as Chief Operating Officer for Crestovo, a clinical-stage biopharmaceutical company focused on microbiome therapies. From 2014 to 2016, Mr. Lobacki served as Chief Commercial Officer at Medivation, Inc., a biopharmaceutical company focused on development of novel therapies for the treatment of serious diseases. From 2012 to 2014, Mr. Lobacki also served as General Manager of Oncology and an independent biotechnology consultant at Idera Pharmaceuticals, Inc., a biopharmaceutical company focused on therapies for cancer and rare diseases. Previously, Mr. Lobacki served as Senior Vice-President and Chief Commercial Officer at Micromet, Inc., Senior Vice-President and General Manager of US Transplant and Oncology at Genzyme Corporation and in various other positions at SangStat Medical Corporation, Cell Pathways, Inc., Rhone-Poulenc Rorer and Lederle Laboratories. Mr. Lobacki previously served on the board of directors of Celator Pharmaceuticals Inc. Mr. Lobacki received a B.S. in Biology from Boston College and a B.S. in Pharmacy from the Massachusetts College of Pharmacy.
As the Independent Director of Sutro Biopharma Inc, the total compensation of Joseph Lobacki at Sutro Biopharma Inc is $128,321. There are 10 executives at Sutro Biopharma Inc getting paid more, with William Newell having the highest compensation of $3,817,120.
Joseph Lobacki is 61, he's been the Independent Director of Sutro Biopharma Inc since 2017. There are 16 older and 3 younger executives at Sutro Biopharma Inc. The oldest executive at Sutro Biopharma Inc is Dr. Shabbir T. Anik, 68, who is the Chief Technical Operations Officer.
Joseph's mailing address filed with the SEC is C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 6 years, insiders at Sutro Biopharma Inc have traded over $14,451,171 worth of Sutro Biopharma Inc stock and bought 750,858 units worth $10,652,478 . The most active insiders traders include Corp /De/ Celgene, John Gordon Freund et Daniel Janney. On average, Sutro Biopharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $129,762. The most recent stock trade was executed by Jane Chung on 9 August 2024, trading 18,750 units of STRO stock currently worth $86,438.
at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll
Sutro Biopharma Inc executives and other stock owners filed with the SEC include: